Bayer Announces Completion of Rolling Submission of New Drug Application in the U.S. for Larotrectinib for the Treatment of TRK Fusion Cancer

WHIPPANY, N.J., March 26, 2018 -- (Healthcare Sales & Marketing Network) -- Bayer today announced that its collaboration partner Loxo Oncology, Inc., (NASDAQ: LOXO) has completed the rolling submission of a New Drug Application (NDA) to the U.S. Food and ... Biopharmaceuticals, Oncology, FDA Bayer, Loxo Oncology, larotrectinib, TRK Fusion Cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news